# USING DYNAMICAL REACTION NETWORK TO INFER DRUGS SELECTIVITY IN PHARMACOLOGY

Romain Yvinec

BIOS, INRA Centre Val-de-Loire

What is Drugs Selectivity?

Some examples


Bias quantification - standard method : operational model

Biased quantification using dynamical model

# Functional selectivity, biased signaling

#### What is Drugs Selectivity?


 Several reaction pathways are generally associated to a given receptor, and lead to various cell response.



# Functional selectivity, biased signaling

#### What is Drugs Selectivity?


- Several reaction pathways are generally associated to a given receptor, and lead to various cell response.
- Differential activation of those reaction pathways, that differs between (natural or synthetic) ligand



# Functional selectivity, biased signaling

#### What is Drugs Selectivity?

- Several reaction pathways are generally associated to a given receptor, and lead to various cell response.
- Differential activation of those reaction pathways, that differs between (natural or synthetic) ligand
- Drugs Selectivity = Ligand-dependent selectivity for certain signal transduction pathways at one given receptor




- ◊ Drugs Selectivity (or Biased Signaling) is a key concept to be distinguish from
  - Partial or full agonist.
  - Antagonist, inverse agonist.
  - Affinity  $(K_d)$ , potency  $(EC_{50})$ , efficacy  $(E_{max})$ .

- ◊ Drugs Selectivity (or Biased Signaling) is a key concept to be distinguish from
  - Partial or full agonist.
  - Antagonist, inverse agonist.
  - Affinity  $(K_d)$ , potency  $(EC_{50})$ , efficacy  $(E_{max})$ .
- A bias might be context-dependent (cell type, physiological state, etc.)

- ◊ Drugs Selectivity (or Biased Signaling) is a key concept to be distinguish from
  - Partial or full agonist.
  - Antagonist, inverse agonist.
  - Affinity  $(K_d)$ , potency  $(EC_{50})$ , efficacy  $(E_{max})$ .
- A bias might be context-dependent (cell type, physiological state, etc.)
- $\diamond\,$  Biased agonism is becoming a major tool in drug discovery.
- $\Rightarrow$  Candidate screening requires to accurately quantify bias.

A receptor may adopt several spatial conformations, each of which has different activation pathway profiles.

Conformational selectivity = Ligand-specific modification of the energetic landscape, changing affinities and efficacies of signaling patways.






Kenakin, J Pharmacol Exp Ther (2011)

# Theoretical foundation

A receptor may adopt several spatial conformations, each of which has different activation pathway profiles.

Conformational selectivity = Ligand-specific modification of the energetic landscape, changing affinities and efficacies of signaling patways.


Similar concept : modulating bias





Kenakin and Christopoulos, Nat. Rev. Drug Discov. (2013)

To speak about signaling bias, one necessarily needs **two** ligands and **two** responses, in a **same** cellular context.



 $\Rightarrow$  We always compare a ligand with respect to a reference one.

What is Drugs Selectivity?

#### Some examples

Bias quantification - standard method : operational model


Biased quantification using dynamical model

# Serotonine receptor $5 - HT_{2C}$

- Quipazine is biaised towards *PI* accumulation with respect to *AA* production, *compared to the reference agonist DOI*.
- LSD is not biased.




```
Berg et al., Mol.
Pharmacol. (1998)
```



# Serotonine receptor $5 - HT_{2C}$


- Quipazine is biaised towards *PI* accumulation with respect to *AA* production, *compared to the reference agonist DOI*.
- LSD is not biased.
- $\Rightarrow \text{ Bias due to an } E_{max}$ difference.





Berg et al., *Mol. Pharmacol.* (1998)

# Serotonine receptor $5 - HT_{2A}$




• (R) - 2C - B - CB is biaised towards *PI* accumulation with respect to *AA* production, *compared to the reference agonist DOB*.



Urban et al., J Pharmacol Exp Ther (2007)

# Serotonine receptor $5 - HT_{2A}$



- (R) 2C B CB is biaised towards *PI* accumulation with respect to *AA* production, *compared to the reference agonist DOB*.
- $\Rightarrow$  Bias due to an *EC*<sub>50</sub> difference.




Urban et al., J Pharmacol Exp Ther (2007)

# Steroidogenesis modulated by NAM

Some negative allosteric modulators (NAM) can biased Progesterone production with respect to Testosterone production, under stimulation of LH/CG receptor by hCG.

Ayoub et al., *Mol. Cell. Endocrinol* (2016)




# Steroidogenesis modulated by NAM

Some negative allosteric modulators (NAM) can biased Progesterone production with respect to Testosterone production, under stimulation of LH/CG receptor by hCG.

 $\Rightarrow$  Selective (biased) allosteric modulation




Ayoub et al., *Mol. Cell. Endocrinol* (2016)



# Many more examples on GPCR (principle drug target)

Many GPCR's are known to have biased ligands ( $G / \beta$ -arrestin)

Kenakin, *Chem Rev* (2017)



What is Drugs Selectivity?

Some examples


#### Bias quantification - standard method : operational model

Biased quantification using dynamical model

Dose-response data are fitted with the function

$$y = E_{tot} \frac{\tau^n [L]^n}{([L] + Ka)^n + \tau^n [L]^n} \,.$$

- Response at equilibrium of a Michaelis-Menten type model.
- *Ka* = **Dissociation constant** of the couple Ligand/Receptor
- $\tau = \text{Efficacy coefficient}$  of the transduction pathway




Dose-response data are fitted with the function

$$y = E_{tot} \frac{\tau^n [L]^n}{([L] + Ka)^n + \tau^n [L]^n} \,.$$

For n = 1,

- $EC_{50} = \frac{\kappa_a}{\tau+1}$
- Efficacy  $y_{\infty}/E_{tot} = \frac{\tau}{\tau+1}$

J. W. Black and P. Leff



Dose-response data are fitted with the function

$$y = E_{tot} \frac{\tau^n [L]^n}{([L] + Ka)^n + \tau^n [L]^n} \,.$$

For n = 1,


- $EC_{50} = \frac{Ka}{\tau+1}$
- Efficacy  $y_{\infty}/E_{tot} = \frac{\tau}{\tau+1}$

Then, we define


⇒ Transduction coefficient :

$$R := \log\left(\frac{\tau}{Ka}\right)$$

J. W. Black and P. Leff




### Bias quantification : with the operational model



**Two** ligands (j = 1, 2) and **two** measured responses (i = 1, 2): Each dose-response data is fitted with the operational model :

$$y_{ij} = E_i \frac{\tau_{ij}^{n_i} [L]^{n_i}}{([L] + Ka_{ij})^{n_i} + \tau_{ij}^{n_i} [L]^{n_i}}$$

### Bias quantification : with the operational model




**Two** ligands (j = 1, 2) and **two** measured responses (i = 1, 2): Each dose-response data is fitted with the operational model :

$$y_{ij} = E_i \frac{\tau_{ij}^{n_i} [L]^{n_i}}{([L] + Ka_{ij})^{n_i} + \tau_{ij}^{n_i} [L]^{n_i}}$$

For a given response *i*, we calculate  $\Delta_i \log(\tau/Ka) = \log(\tau_{i2}/Ka_{i2}) - \log(\tau_{i1}/Ka_{i1}).$ 

# Bias quantification : with the operational model




**Two** ligands (j = 1, 2) and **two** measured responses (i = 1, 2): Each dose-response data is fitted with the operational model :

$$y_{ij} = E_i \frac{\tau_{ij}^{n_i} [L]^{n_i}}{([L] + Ka_{ij})^{n_i} + \tau_{ij}^{n_i} [L]^{n_i}}.$$

For a given response *i*, we calculate  $\Delta_i \log(\tau/Ka) = \log(\tau_{i2}/Ka_{i2}) - \log(\tau_{i1}/Ka_{i1}).$ The **Bias** is then defined by

$$\Delta\Delta\log( au/ extsf{Ka}) = \Delta_2\log( au/ extsf{Ka}) - \Delta_1\log( au/ extsf{Ka})$$

# Statistical consideration : parameter confidence interval and (un-)identifiability



What is Drugs Selectivity?

Some examples

Bias quantification - standard method : operational model

Biased quantification using dynamical model


# Time-dependent bias?

# The role of kinetic context in apparent biased agonism at GPCRs

Carmen Klein Herenbrink<sup>1</sup>, David A. Sykes<sup>2</sup>, Prashant Donthamsetti<sup>3,4</sup>, Meritxell Canals<sup>1</sup>, Thomas Coudrat<sup>1</sup>, Jeremy Shonberg<sup>5</sup>, Peter J. Scammells<sup>5</sup>, Ben Capuano<sup>5</sup>, Patrick M. Sexton<sup>1</sup>, Steven J. Charlton<sup>2</sup>, Jonathan A. Javitch<sup>3,4,6</sup>, Arthur Christopoulos<sup>1</sup> & J Robert Lane<sup>1</sup>

- Bias value may change according to the response time after stimulation.
- Kinetic explanation : Ligands with a slow binding kinetics may have changing bias value according to time.

Klein Herenbrink et al., *Nat. Commun* (2016)




# Time-dependent bias?

# The role of kinetic context in apparent biased agonism at GPCRs


Carmen Klein Herenbrink<sup>1</sup>, David A. Sykes<sup>2</sup>, Prashant Donthamsetti<sup>3,4</sup>, Meritxell Canals<sup>1</sup>, Thomas Coudrat<sup>1</sup>, Jeremy Shonberg<sup>5</sup>, Peter J. Scammells<sup>5</sup>, Ben Capuano<sup>5</sup>, Patrick M. Sexton<sup>1</sup>, Steven J. Charlton<sup>2</sup>, Jonathan A. Javitch<sup>3,4,6</sup>, Arthur Christopoulos<sup>1</sup> & J Robert Lane<sup>1</sup>

- Bias value may change according to the response time after stimulation.
- Kinetic explanation : Ligands with a slow binding kinetics may have changing bias value according to time.
- ⇒ We need to take into account dynamic patterns in bias quantification




# Dynamic data (on FHSR in HEK cells)

Instead of focusing on dose-response curves, we deal with **kinetic data** performed at several doses (here : induced BRET data)




# Dynamic data (on FHSR in HEK cells)


Instead of focusing on dose-response curves, we deal with **kinetic data** performed at several doses (here : induced BRET data)




I)We start with a sufficiently detailed chemical reaction network




**I)**We start with a sufficiently detailed chemical reaction network to accurately fit the data (one **separate** model for each Ligand)




**II)** We fit **all data at once**, using some **common** parameters (initial concentration of molecules, measurement parameters...) and some **different** ones (kinetic parameters...)



**II)** We fit **all data at once**, using some **common** parameters (initial concentration of molecules, measurement parameters...) and some **different** ones (kinetic parameters...)




III) We use  $L^1$ -penalization to find ligand specific parameters






Data2Dyanmics : Steiert, Timmer and Kreutz, *Bioinformatics* (2016)

**III)** We use  $L^1$ -penalization to find **ligand specific parameters**, keeping the fit 'as good as before'




Steiert, Timmer and Kreutz, Bioinformatics (2016)

IV) After re-optimization, the set of distinct (ligand-specific) kinetic parameters gives us an accurate description of ligand specificity.




V) Significant differences between parameters is assessed by PLE





→here : C3 is biased towards  $\beta$ -arr, compared to cAMP, in comparison to FSH.

## Practical problems...





#### Practical problems...






We obtain a slightly worse fit







And "better" parameter identifiability



C3 is biased towards  $\beta$ -arr, compared to cAMP, in comparison to FSH.




We systematically calculate bias value using standard method (operational model on dose-response curves :)




Bias=2.3 : C1 is biased towards  $\beta$ -arr, compared to cAMP, in comparison to FSH.

We systematically calculate bias value using standard method (operational model on dose-response curves :)




Bias=2.64 : C1 is biased towards  $\beta$ -arr, compared to cAMP, in comparison to FSH.

We systematically calculate bias value using standard method Different times gives (slightly) different bias values



C1 is biased towards  $\beta$ -arr, compared to cAMP, in comparison to FSH

We systematically calculate bias value using standard method Uncertainty can be large according to the time of measurement



- Notion of signaling bias to quantify differential activation of several pathways by a Ligand at a given receptor.
- Standard quantification has several drawbacks (no time, limited to sigmoid scenario, et).
- We gave a kinetic interpretation of Ligand biased, which rely on dynamic (ODE) modeling and parameter estimation with  $L^1$  penalization.

- Notion of signaling bias to quantify differential activation of several pathways by a Ligand at a given receptor.
- Standard quantification has several drawbacks (no time, limited to sigmoid scenario, et).
- We gave a kinetic interpretation of Ligand biased, which rely on dynamic (ODE) modeling and parameter estimation with  $L^1$  penalization.
- $\Rightarrow$  How to deal with "fuzzy/noisy" PLE / Densely sampled time data ?
- $\Rightarrow$  How to deal with non uniqueness of the penalized solution?
- ⇒ How to perform a model reduction that would lead to both a satisfactory fit and identifiable parameters?

### Thanks for your attention !

#### Bios Team, PRC, INRA (Tours, Fr)

- ★ Eric Reiter
- \* Pascale Crépieux
- ⋆ Anne Poupon
- \* Francesco De Pascali

#### United Arab Emirates University

\* Mohammed Ayoub





M. Ayoub et al., Molecular and Cellular Endocrinology 436 (2016)

L. Riccetti et al., Scientific Reports 7 :940 (2017)


R.Y. et al., Methods in Molecular Biology, in press (2018)









Original "raw" data



#### "Adjusted" data



"Adjusted" data



#### Dose-dependent bias



Barak and Peterson et al., *Biochem.* (2012)


Extension of the operational model




Kenakin, *Chem. Rev.* (2017) Method based on Intrinsic activities and rank ordering




Onaran et al., *Sci. Rep.* (2017)







A strong bias is usually 'apparent' on dose-response curves or bias plot



But there may be counter-intuitive situation...



But there may be counter-intuitive situation...



But there may be counter-intuitive situation...

... and those situations occur in real life!

